News

Ipsen and Debiopharm has signed an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen’s first-in-class inhibitor of the CDC25 phosphatase enzyme

Pfizer on Friday announced that it has plans to launch two or three generic drugs in India by December, reported Indiainfoline. It is an attempt to boost sales

Stemedica Cell Technologies has signed an agreement for its breakthrough stem cell and related technology. The Jordanian Stem Cell Company has signed a five year multi-million dollar agreement

Chugai Pharmaceutical has announced to increase the supply of the anti-influenza drug Tamiflu Capsule 75 and Tamiflu Dry Syrup 3% (oseltamivir phosphate) imported from F Hoffmann-La Roche for

Speciality European Pharma (SEP) has launched Regurin XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) in the UK. Regurin XL is licensed

Sanofi Pasteur, the vaccines division of Sanofi-aventis, has signed an agreement with Butantan Institute for the production and supply of a vaccine against the new A(H1N1) influenza virus

Meda and Cipla have expanded the existing long term collaboration agreement for the combination of azelastine and fluticasone. Azelastine is an antihistamine and fluticasone a corticosteroid, indicated for

Aurobindo Pharma (Aurobindo) has received two approvals from Swissmedic, Government of Switzerland for the license of Amlodipine APL 5mg and 10mg tablets and Metformin APL 500mg, 850mg and

French healthcare diagnostics group, bioMerieux, reported an increase in sales by 11.6% to E589.5m from E528.2m for the first-half of previous year. bioMerieux posted net profit in the